Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Towards a better understanding of how medicines are used in society Drug Utilization Research (DUR) is a discipline which combines aspects of pharmacotherapy, epidemiology, and health services research into an interdisciplinary set of methods for analyzing and assessing the prescribing, dispensing and consumption of medicines. It combines both qualitative and quantitative approaches to facilitate the safe and effective use of pharmaceuticals. Drug Utilization Research: Methods and Applications provides a comprehensive introduction to this discipline, prepared by an international team of…mehr
Towards a better understanding of how medicines are used in society
Drug Utilization Research (DUR) is a discipline which combines aspects of pharmacotherapy, epidemiology, and health services research into an interdisciplinary set of methods for analyzing and assessing the prescribing, dispensing and consumption of medicines. It combines both qualitative and quantitative approaches to facilitate the safe and effective use of pharmaceuticals. Drug Utilization Research: Methods and Applications provides a comprehensive introduction to this discipline, prepared by an international team of authors with broad experience in numerous fields. Now reorganized and updated to reflect the latest research and global challenges, it is an indispensable resource for understanding the use of pharmaceuticals.
Readers of the second edition of Drug Utilization Research will find:
New chapters on methods, including more hands-on guidance on how to plan and conduct different types of drug utilization
A section on specific applications in areas such as psychotropics, opioids, cancer drugs, antibacterials, and cardiovascular drugs
A new section with case studies illustrating applications of DUR in different continents
Detailed treatment of subjects including DUR and health policy, DUR in specific populations, and many more
Drug Utilization Research is ideal for epidemiologists, pharmacists, physicians, nurses and others interested in drug use and its outcomes.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in D ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Autorenporträt
Editors Monique Elseviers, Björn Wettermark, Tanja Mueller, Ria Benk¿, Marion Bennie, Katarina Gvozdanovi¿, Mikael Hoffmann, Irina Iaru, Verica Ivanovska, Seán MacBride-Stewart, Elisabetta Poluzzi, Lisa Pont, Hege Salvesen Blix, Gabriel Sanfélix-Gimeno, Gisbert Selke, Katja Taxis, Ana Tomas Petrovi¿, Indr¿ Tre¿iokien¿, Sabine Vogler
Inhaltsangabe
List of contributors ix Preface to the second edition xvii Acknowledgements xix About the companion website xxiii Part 1 Introduction to drug utilization research 1 1 Introduction to drug utilization research 3 Björn Wettermark, Monique Elseviers, Tanja Mueller, Anna Birna Almarsdottir, Ria Benkö, Marion Bennie, Irina Iaru, Katarina Gvozdanovic, Mikael Hoffmann, Verica Ivanovska, Seán MacBride-Stewart, Elisabetta Poluzzi, Lisa G. Pont, Hege Salvesen Blix, Gabriel Sanfelix-Gimeno, Gisbert W. Selke, Katja Taxis, Ana Tomas Petrovic, Indre Treciokiene, and Sabine Vogler Part 2 Methodology of drug utilization research 15 2.1 Research methods in drug utilization research 17 Björn Wettermark, Indre Treciokiene, Sofia Kälvemark Sporrong, and Louise C. Druedahl 2.2 Qualitative methods in drug utilization research 25 Louise C. Druedahl and Sofia Kälvemark Sporrong 2.3 Quantitative studies in drug utilization research 41 Björn Wettermark, Monique Elseviers, and Cristina Mihaela Ghiucic 2.4 Descriptive studies in drug utilization research 51 Cristina Mihaela Ghiciuc, Indre Treciokiene, Björn Wettermark, and Monique Elseviers 2.5 Analytical studies in drug utilization research 63 Per-Jostein Samuelsen, Björn Wettermark, and Monique Elseviers 2.6 Intervention studies in drug utilisation research 73 Tanja Mueller, Giampiero Mazzaglia, and Carlos E. Durán 2.7 Statistics in drug utilization research 82 Monique Elseviers 2.8 Primary drug utilization data 95 Tatiana Chama Borges Luz and Evalill Nilsson 2.9 Secondary drug utilization data 104 Mohammadhossein Hajiebrahimi, Lisa G. Pont, and Kristina Garuoliene 2.10 Classification systems in drug utilization 115 Hege Salvesen Blix, Stuart McTaggart, and Robert Vander Stichele 2.11 Measuring volumes in drug utilization 126 Hege Salvesen Blix and Mikael Hoffmann 2.12 Measuring price and expenditure in drug utilization 137 Sabine Vogler 2.13 Aggregate-level drug utilization analyses 148 Indre Treciokiene and Claudia Garcia Serpa Osorio-de-Castro 2.14 Individual-level drug utilization analyses 158 Lotte Rasmussen, Björn Wettermark, Mikael Hoffmann, and Douglas Steinke 2.15 Multilevel analyses in drug utilization research 169 Juan Merlo and George Leckie 2.16 Visualization of drug utilization data 188 Maria Matuz, Ria Benko, and Mikael Hoffmann 2.17 Artificial intelligence and machine learning in drug utilization research 205 Maurizio Sessa, Saeed Shakibfar, Morten Andersen, and Jing Zhao 2.18 Ethics in drug utilization research 215 Indre Treciokiene, Sofia Kälvemark Sporrong, Björn Wettermark, and Louise C. Druedahl Part 3 Applied drug utilization research 223 Section 3.1 Drug utilization research and health policy 225 3.1.1 Pharmaceutical policy and drug utilization: Definitions, concepts, and taxonomies 225 Sabine Vogler and Anna Birna Almarsdóttir 3.1.2 Managed introduction of new medicines in healthcare systems 233 Irina Iaru and Sabine Vogler 3.1.3 Promoting appropriate use of medicines in a healthcare system 248 Marion Bennie, Amanj Kurdi, and Yared Santa-Ana-Téllez Section 3.2 Comparative drug utilization research 258 3.2.1 Introduction to comparative drug utilization research 258 Seán MacBride-Stewart and Ana Tomas Petrovic 3.2.2 Comparison of drug utilization across countries 260 Yared Santa-Ana Tellez and Monique Elseviers 3.2.3 Comparative drug utilization research comparing regions within countries 271 Seán MacBride-Stewart 3.2.4 Comparison of drug utilization across different prescribers and different health care settings 280 Seán MacBride-Stewart, Ksenia Zagorodnikova, and Irene Langner 3.2.5 Comparative drug utilization research comparing different patients 292 Ana Tomas Petrovic and Mia von Euler Section 3.3 Drug utilization research in specific populations 303 3.3.1 Drug utilization in pregnant women 303 Hedvig Nordeng and Marleen van Gelder 3.3.2 Drug utilization in the paediatric population 314 Antonio Clavenna and Ingvild Odsbu 3.3.3 Drug utilization in older people 321 Petra Denig and Katharina Schmidt-Mende Section 3.4 Drug utilization research in specific therapeutic areas 331 3.4.1 Introduction to methodological issues in specific therapeutic areas 331 3.4.2 Drug utilization research on cardiovascular medicines 332 Elisabetta Poluzzi, Ana Tomas Petrovic, and Björn Wettermark 3.4.3 Drug utilization research on antibacterials 342 Ria Benko and Samuel Coenen 3.4.4 Drugs utilization research in specific therapeutic areas - opioids 352 Aleksi Hamina, Svetlana Skurtveit, and Mikael Hoffmann 3.4.5 Drug utilization research on selected psychotropics 363 Jonathan Brett and Helga Zoega 3.4.6 Drug utilization research in the area of cancer drugs 373 Tanja Mueller and Mikael Hoffmann Section 3.5 Adherence and drug utilization research 381 3.5.1 Introduction to medication adherence research 381 Bernard Vrijens 3.5.2 Assessment of medication adherence in field research 387 Monique Elseviers and Bernard Vrijens 3.5.3 Assessment of medication adherence in databases 397 Gabriel Sanfélix Gimeno and Tanja Mueller 3.5.4 Interventions to improve medication adherence 406 Catherine Goetzinger and Marie P. Schneider 3.5.5 Digital tools and medication adherence 419 Alexandra L. Dima, Urska Nabergoj-Makovec, and Job F.M. van Boven Section 3.6 The role of drug utilization in the broader field of health research 428 3.6.1 Risk management and drug utilization research 428 Giampiero Mazzaglia, Ippazio Cosimo Antonazzo, and Peter Mol 3.6.2 Pharmacovigilance and drug utilization research 437 Katarina Gvozdanovic, Bernard Begauld, and Emanuel Raschi 3.6.3 The role of drug utilization in outcomes research 445 Henrik Toft Sørensen, Gianluca Trifirò, and Evalill Nilsson 3.6.4 Pharmacoeconomics and drug utilization research 456 Cara Usher, Kathleen Bennett, Lorenzo G. Mantovani, and Dyfrig Hughes 3.6.5 The environment and drug utilisation research 464 Marmar Nekoro, Johanna Villén, and Ana Tomas Petrovic Section 3.7 Assessment and improvement of the quality of medicine use 482 3.7.1 Defining the quality of medicines use 482 Seán MacBride-Stewart 3.7.2 Assessing the quality of medication use 488 Petra Denig, Björn Wettermark, and Wade Thompson 3.7.3 Challenges in the quality of medicine use 498 Katja Taxis and Carl Llor 3.7.4 Development and evaluation of interventions to improve the quality of medicine use 505 Seán MacBride-Stewart and Katja Taxis 3.7.5 Implementation of interventions to enhance quality use of medicines 517 Liset van Dijk and Marcia Vervloet 3.7.6 Patient perspectives 525 Janine Traulsen and Janet Krska Part 4 Drug utilization research around the world 535 4.1 Introduction to drug utilization research around the world 537 Monique Elseviers 4.2 Drug utilization research in Africa 541 Ilse Truter, Johanita Burger, and Joseph Fadare 4.3 Drug utilization research in the Eastern Mediterranean region 546 Mamoon A. Aldeyab, Zainab Said Al-Hashimy, and Maha Talaat 4.4 Drug utilization research in South-East Asia 551 Anita Kotwani, Nithima Sumpradit, and Aminath Moomina 4.5 Drug utilization research in the Western Pacific Region 557 Lisa G. Pont, Tuan Anh Nguyen, and Elizabeth Roughead 4.6 Drug utilization research in North America 563 Juan M. Hincapie-Castillo, Shawn Bugden, and Ingrid Sketris 4.7 Drug utilization research in South and Central America 569 Claudia Garcia Serpa Osorio-de-Castro, Luciane Cruz Lopes, and Carlos E. Durán 4.8 Drug utilization research in Europe 574 Marion Bennie, Lotte Rasmussen, and Janne Sepp 4.9 The Glasgow Declaration 580 Monique Elseviers, Björn Wettermark, Tanja Mueller, Anna Birna Almarsdottir, Ria Benkö, Marion Bennie, Irina Iaru, Katarina Gvozdanovic, Mikael Hoffmann, Verica Ivanovska, Seán MacBride-Stewart, Elisabetta Poluzzi, Lisa G. Pont, Hege Salvesen Blix, Gabriel Sanfelix-Gimeno, Gisbert W. Selke, Katja Taxis, Ana Tomas Petrovic, Indre Treciokiene, and Sabine Vogler Index 583
List of contributors ix Preface to the second edition xvii Acknowledgements xix About the companion website xxiii Part 1 Introduction to drug utilization research 1 1 Introduction to drug utilization research 3 Björn Wettermark, Monique Elseviers, Tanja Mueller, Anna Birna Almarsdottir, Ria Benkö, Marion Bennie, Irina Iaru, Katarina Gvozdanovic, Mikael Hoffmann, Verica Ivanovska, Seán MacBride-Stewart, Elisabetta Poluzzi, Lisa G. Pont, Hege Salvesen Blix, Gabriel Sanfelix-Gimeno, Gisbert W. Selke, Katja Taxis, Ana Tomas Petrovic, Indre Treciokiene, and Sabine Vogler Part 2 Methodology of drug utilization research 15 2.1 Research methods in drug utilization research 17 Björn Wettermark, Indre Treciokiene, Sofia Kälvemark Sporrong, and Louise C. Druedahl 2.2 Qualitative methods in drug utilization research 25 Louise C. Druedahl and Sofia Kälvemark Sporrong 2.3 Quantitative studies in drug utilization research 41 Björn Wettermark, Monique Elseviers, and Cristina Mihaela Ghiucic 2.4 Descriptive studies in drug utilization research 51 Cristina Mihaela Ghiciuc, Indre Treciokiene, Björn Wettermark, and Monique Elseviers 2.5 Analytical studies in drug utilization research 63 Per-Jostein Samuelsen, Björn Wettermark, and Monique Elseviers 2.6 Intervention studies in drug utilisation research 73 Tanja Mueller, Giampiero Mazzaglia, and Carlos E. Durán 2.7 Statistics in drug utilization research 82 Monique Elseviers 2.8 Primary drug utilization data 95 Tatiana Chama Borges Luz and Evalill Nilsson 2.9 Secondary drug utilization data 104 Mohammadhossein Hajiebrahimi, Lisa G. Pont, and Kristina Garuoliene 2.10 Classification systems in drug utilization 115 Hege Salvesen Blix, Stuart McTaggart, and Robert Vander Stichele 2.11 Measuring volumes in drug utilization 126 Hege Salvesen Blix and Mikael Hoffmann 2.12 Measuring price and expenditure in drug utilization 137 Sabine Vogler 2.13 Aggregate-level drug utilization analyses 148 Indre Treciokiene and Claudia Garcia Serpa Osorio-de-Castro 2.14 Individual-level drug utilization analyses 158 Lotte Rasmussen, Björn Wettermark, Mikael Hoffmann, and Douglas Steinke 2.15 Multilevel analyses in drug utilization research 169 Juan Merlo and George Leckie 2.16 Visualization of drug utilization data 188 Maria Matuz, Ria Benko, and Mikael Hoffmann 2.17 Artificial intelligence and machine learning in drug utilization research 205 Maurizio Sessa, Saeed Shakibfar, Morten Andersen, and Jing Zhao 2.18 Ethics in drug utilization research 215 Indre Treciokiene, Sofia Kälvemark Sporrong, Björn Wettermark, and Louise C. Druedahl Part 3 Applied drug utilization research 223 Section 3.1 Drug utilization research and health policy 225 3.1.1 Pharmaceutical policy and drug utilization: Definitions, concepts, and taxonomies 225 Sabine Vogler and Anna Birna Almarsdóttir 3.1.2 Managed introduction of new medicines in healthcare systems 233 Irina Iaru and Sabine Vogler 3.1.3 Promoting appropriate use of medicines in a healthcare system 248 Marion Bennie, Amanj Kurdi, and Yared Santa-Ana-Téllez Section 3.2 Comparative drug utilization research 258 3.2.1 Introduction to comparative drug utilization research 258 Seán MacBride-Stewart and Ana Tomas Petrovic 3.2.2 Comparison of drug utilization across countries 260 Yared Santa-Ana Tellez and Monique Elseviers 3.2.3 Comparative drug utilization research comparing regions within countries 271 Seán MacBride-Stewart 3.2.4 Comparison of drug utilization across different prescribers and different health care settings 280 Seán MacBride-Stewart, Ksenia Zagorodnikova, and Irene Langner 3.2.5 Comparative drug utilization research comparing different patients 292 Ana Tomas Petrovic and Mia von Euler Section 3.3 Drug utilization research in specific populations 303 3.3.1 Drug utilization in pregnant women 303 Hedvig Nordeng and Marleen van Gelder 3.3.2 Drug utilization in the paediatric population 314 Antonio Clavenna and Ingvild Odsbu 3.3.3 Drug utilization in older people 321 Petra Denig and Katharina Schmidt-Mende Section 3.4 Drug utilization research in specific therapeutic areas 331 3.4.1 Introduction to methodological issues in specific therapeutic areas 331 3.4.2 Drug utilization research on cardiovascular medicines 332 Elisabetta Poluzzi, Ana Tomas Petrovic, and Björn Wettermark 3.4.3 Drug utilization research on antibacterials 342 Ria Benko and Samuel Coenen 3.4.4 Drugs utilization research in specific therapeutic areas - opioids 352 Aleksi Hamina, Svetlana Skurtveit, and Mikael Hoffmann 3.4.5 Drug utilization research on selected psychotropics 363 Jonathan Brett and Helga Zoega 3.4.6 Drug utilization research in the area of cancer drugs 373 Tanja Mueller and Mikael Hoffmann Section 3.5 Adherence and drug utilization research 381 3.5.1 Introduction to medication adherence research 381 Bernard Vrijens 3.5.2 Assessment of medication adherence in field research 387 Monique Elseviers and Bernard Vrijens 3.5.3 Assessment of medication adherence in databases 397 Gabriel Sanfélix Gimeno and Tanja Mueller 3.5.4 Interventions to improve medication adherence 406 Catherine Goetzinger and Marie P. Schneider 3.5.5 Digital tools and medication adherence 419 Alexandra L. Dima, Urska Nabergoj-Makovec, and Job F.M. van Boven Section 3.6 The role of drug utilization in the broader field of health research 428 3.6.1 Risk management and drug utilization research 428 Giampiero Mazzaglia, Ippazio Cosimo Antonazzo, and Peter Mol 3.6.2 Pharmacovigilance and drug utilization research 437 Katarina Gvozdanovic, Bernard Begauld, and Emanuel Raschi 3.6.3 The role of drug utilization in outcomes research 445 Henrik Toft Sørensen, Gianluca Trifirò, and Evalill Nilsson 3.6.4 Pharmacoeconomics and drug utilization research 456 Cara Usher, Kathleen Bennett, Lorenzo G. Mantovani, and Dyfrig Hughes 3.6.5 The environment and drug utilisation research 464 Marmar Nekoro, Johanna Villén, and Ana Tomas Petrovic Section 3.7 Assessment and improvement of the quality of medicine use 482 3.7.1 Defining the quality of medicines use 482 Seán MacBride-Stewart 3.7.2 Assessing the quality of medication use 488 Petra Denig, Björn Wettermark, and Wade Thompson 3.7.3 Challenges in the quality of medicine use 498 Katja Taxis and Carl Llor 3.7.4 Development and evaluation of interventions to improve the quality of medicine use 505 Seán MacBride-Stewart and Katja Taxis 3.7.5 Implementation of interventions to enhance quality use of medicines 517 Liset van Dijk and Marcia Vervloet 3.7.6 Patient perspectives 525 Janine Traulsen and Janet Krska Part 4 Drug utilization research around the world 535 4.1 Introduction to drug utilization research around the world 537 Monique Elseviers 4.2 Drug utilization research in Africa 541 Ilse Truter, Johanita Burger, and Joseph Fadare 4.3 Drug utilization research in the Eastern Mediterranean region 546 Mamoon A. Aldeyab, Zainab Said Al-Hashimy, and Maha Talaat 4.4 Drug utilization research in South-East Asia 551 Anita Kotwani, Nithima Sumpradit, and Aminath Moomina 4.5 Drug utilization research in the Western Pacific Region 557 Lisa G. Pont, Tuan Anh Nguyen, and Elizabeth Roughead 4.6 Drug utilization research in North America 563 Juan M. Hincapie-Castillo, Shawn Bugden, and Ingrid Sketris 4.7 Drug utilization research in South and Central America 569 Claudia Garcia Serpa Osorio-de-Castro, Luciane Cruz Lopes, and Carlos E. Durán 4.8 Drug utilization research in Europe 574 Marion Bennie, Lotte Rasmussen, and Janne Sepp 4.9 The Glasgow Declaration 580 Monique Elseviers, Björn Wettermark, Tanja Mueller, Anna Birna Almarsdottir, Ria Benkö, Marion Bennie, Irina Iaru, Katarina Gvozdanovic, Mikael Hoffmann, Verica Ivanovska, Seán MacBride-Stewart, Elisabetta Poluzzi, Lisa G. Pont, Hege Salvesen Blix, Gabriel Sanfelix-Gimeno, Gisbert W. Selke, Katja Taxis, Ana Tomas Petrovic, Indre Treciokiene, and Sabine Vogler Index 583
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
